[Federal Register: November 19, 2004 (Volume 69, Number 223)] [Notices] [Page 67746-67747] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr19no04-62] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2004D-0460] Draft Guidance for Industry on Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003--Questions and Answers; Availability; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of November 4, 2004. This document announced the availability of a draft guidance for industry entitled ``Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003-- Questions and Answers.'' The document was published with an incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Joyce A. Strong, Office of Policy (HF- 27), Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857, 301-827-7010. SUPPLEMENTARY INFORMATION: In FR Doc. 04-24675, appearing on page 64314 in the Federal Register of Thursday, November 4, 2004, the following correction is made: 1. On page 64314, in the second column, ``Docket No. 2004N-0087'' is corrected to read ``Docket No. 2004D-0460''. [[Page 67747]] Dated: November 12, 2004. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 04-25647 Filed 11-18-04; 8:45 am] BILLING CODE 4160-01-S